RESUMO
There are several progresses in colorectal cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology (CSCO).(1) Phase Ⅲ multi-center trial FRESCO and TERRA study have showed domestic new drug Fruquintinib and Japanese oral combination anti-cancer drug TAS-102 significantly improved overall survival (OS) comparing to placebo in third-line metastatic colorectal cancer (mCRC) patients.(2) Preoperative neoadjuvant chemotherapy with mFOLFOXIRI and selective radiotherapy or concomitant boost neoadjuvant chemoradiotherapy (nCRT) followed by one cycle of XELOX,can improve short-term outcome for locally advanced rectal cancer,and clinical and pathological features can be used to predict complete response following nCRT.(3) In asymptomatic elderly population,the specificity of septin9 methylation detection in plasma cfDNA as colorectal cancer screening is low,but the probability of negative predictions as non-colorectal cancer is high.And integrated signature of the gut microbiome and metabolome serves as diagnostic biomarkers in patients with colorectal cancer.(4) Immunoscore system predicts prognosis after liver metastasectomy in colorectal metastases,and the immune signature difference between right and left colon cancer could explain the difference of targeted therapy.